Anglo-Irish company Healthcare 21 Group, one of Northern Europe’s largest privately-owned healthcare companies, has completed the acquisition of Gloucestershire-based Xograph Healthcare.
Xograph, founded in 1967 and based in Stonehouse, is the largest independent medical imaging equipment supplier throughout the UK and Ireland serving NHS and HSE hospitals, private hospitals, clinics and diagnostic centres. It provides innovative medical imaging technology, supported by a nationwide team of highly trained field-based engineers and clinical applications specialists.
Owen Curtin, chairman of Healthcare 21 Group, said: “The acquisition of Xograph Healthcare maintains our exciting programme of growth and expansion, accelerating our drive to become a pan European, best-in-class provider of specialist sales, marketing and technical service solutions for our world leading healthcare and scientific supplier partners.
“Acquiring Xograph confirms our commitment to the highly innovative MedTech and Diagnostic Technical services industry. The Xograph business, combined with our existing teams, now makes the Healthcare 21 Group one the largest players in the sector across the UK and Irish healthcare market.”
The newly combined business will employ up to 500 staff in the UK, Ireland, Germany and Austria, with a turnover in excess of £135m, representing more than a hundred Original Equipment Manufacturers across its four European markets.
Xograph managing director, Paul Andrews, said: “What an exciting time this is. I am so proud to be leading Xograph Healthcare through one of the most dynamic periods in the Company’s 53-year history. As the newest member of the Healthcare 21 team we can now realise new growth potential, share best practices with other HC21 business units and deliver customer service excellence with every interaction.”
This latest acquisition is another milestone in the significant expansion of the Healthcare 21 Group that, in fewer than three years, has seen the company nearly triple in size.
The Group is focussed on increasing its portfolio scope within its existing partners in addition to continuing to look for new partners and acquisition opportunities as it targets further UK, Irish and European expansion.